Cefoperazone sulbactam

The antimicrobial susceptibility testing of all isolates was done by the disk diffusion method on Mueller-Hinton agar. Apart from this, the minimum inhibitory concentrations (MICs) were also determined by the Vitek2 compact system (using AST GN cards; Biomeriux, France). The interpretation of zone diameters and MICs was done according to each year’s CLSI guidelines.
Escherichia coliATCC 25922 was taken as the control strains. The following antimicrobials (Himedia, India) were tested: ceftazidime (30 μg), cefotaxime (30 μg), ceftriaxone (30 μg), cefoxitin (30 μg), cefepime (30 μg), piperacillin (100 µg), piperacillin-tazobactam (100/10 μg), ticarcillin-clavulanate (75/10 μg), cefoperazone-sulbactam (75/30 μg), cefepime-tazobactam (30/10 µg), ceftriaxone- sulbactam (30/15 µg), imipenem (10 μg), meropenem (10 μg), ertapenem (10 μg), amikacin (30 μg), gentamicin (10 μg), netilmicin (30 μg), tobramycin (10 μg), tetracycline (30 µg), Trimethoprim-sulfamethoxazole (1.25/24 µg), ciprofloxacin (5 μg), levofloxacin (5 μg), tigecycline (15 μg), nitrofurantoin (300 μg), and chloramphenicol (30 μg).
We interpreted the zone diameters and MICs of the isolates as per CLSI recommendations, 2018.
13

“Antimicrobial susceptibility testing” (AST) was performed using modified Kirby–Bauer disk diffusion method following the guidelines of Clinical and Laboratory Standards Institute guidelines (CLSI).33 Sixteen common antibiotic discs from HiMedia: meropenem (10µg), amoxycillin (10µg), cefotaxime (30µg), cefixime (30µg), ceftriaxone (30µg), ceftazidime (30µg), cefoxitin (30µg), cotrimoxazole (25µg), nitrofurantoin (300µg), levofloxacin (5µg), amikacin (30µg), gentamicin (10µg), cefoperazone/sulbactam (75/30µg), piperacillin/tazobactam (100/10µg), imipenem (10µg), doxycycline (30µg) were used. E. coli that were resistant to at least one agent in three or more antibiotic categories were characterized as multidrug-resistant E. coli.34 (link)